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Abstract:
Background: Studies have documented more rapid progression of HCV-associated liver fibrosis in patients co-infected
with HIV. However, the natural history of HCV infection in both mono-infected and HIV co-infected patients remains
highly variable. The patterns and predictors of fibrosis progression in the HIV/HCV co-infected population are not
fully characterized. Given the invasiveness of serial liver biopsies, Fibrosis-4 score (FIB-4), a composite of serum
biomarkers that correlate well with fibrosis stage, is increasingly used. We used FIB-4 to study the natural history of
liver fibrosis progression among co-infected patients and evaluated predictors of progression to cirrhosis over 5 years
prior to treatment with direct acting agents (DAAs).
Methods: Study subjects were selected from HIV/HCV co-infected patients receiving care at Yale-New Haven
Hospital from February 2014 through April 2016 without advanced fibrosis 5 years prior to study entry. Annual FIB-4
scores dating back 5 years were calculated from the most recent FIB-4 score or the last FIB-4 prior to DAA treatment
initiation. Baseline demographics and clinical characteristics including HCV genotype, antiretroviral regimen, HIV
viral loads and CD4 counts were collected. Patients were further categorized based on FIB-4 progression over the
course of 5 years. Univariate and multivariable logistic regression models were used to examine factors associated with
FIB-4 progression and a p-value of 0.05 was chosen as the threshold for statistical significance.
Results: There were 93 patients evaluated including 65 men and 28 women; mean age of 56.7 years; 32.3% were
white, 53.8% were black. Injection drug use (IDU) was the major risk factor for HCV acquisition (63.4%) and the most
common genotype was genotype 1 (81.2%). The median CD4+ count was 564 cells/mm3, and the majority (88.4%) had
HIV viral loads <50 copies/mL. Over 5 years, 25 (26.9%) had FIB-4 progress to >3.25 and 68 (73.1%) had FIB-4
remain <3.25. Demographic variables (age, gender, race/ethnicity, BMI, substance use), clinical variables (HIV viral
load, CD4 count, ART use, HIV duration, HCV duration and viral load) and co-morbid conditions such as diabetes and
hyperlipidemia did not differ significantly between those whose FIB-4 stayed below 3.25 and those whose FIB-4
progressed to above 3.25 in univariate and multivariable logistic regression models.
Conclusion: In this study of 93 HIV/HCV co-infected patients without baseline advanced fibrosis, 26.9% progressed to
advanced fibrosis over the course of 5 years. We did not identify any statistically significant factors that predicted those
who were more likely to progress, although clinically relevant factors such as absence of HIV virologic control, low
CD4 count, and lack of statin use showed a trend towards significance and should be assessed in future studies in a
larger cohort. Our findings highlight the importance of prioritizing all patients with HCV/HIV co-infection for HCV
treatment.
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Introduction:
With the advent of combination antiretroviral therapy (cART), HIV infection has
been transformed from a rapidly fatal disease to a manageable chronic illness. However,
the threat of opportunistic infections, which were the most frequent cause of mortality in
the pre-cART era, has been replaced by complications associated with aging and longterm HIV infection, including cardiovascular disease, lung disease, certain cancers, and
liver disease. Chronic liver disease is the 2nd leading cause of mortality in the HIVinfected population, of which the majority are secondary to hepatitis C virus (HCV)
infection. (1) Liver disease-related deaths have increased markedly in the HIV-infected
population in the post-cART era, coinciding with the peak of HCV-related disease burden
epidemiologically. (2)
It is estimated that of over 33.3 million people living with HIV infection globally,
approximately 20-30% are co-infected with HCV due to shared routes of disease
transmission, including parenteral (injection drug use, blood transfusion), perinatal, and
sexual. (3) The incidence of HIV/HCV coinfection ranges from 10% to over 80% among
those who acquire HIV by intravenous drug use. (4) Chronic HCV infection is not only
associated with liver-specific health outcomes such as cirrhosis, liver failure, and
hepatocellular carcinoma (HCC), but has also been associated with increased
cardiovascular morbidity, renal dysfunction, insulin resistance, and cancer. (2) Given the
wide array of adverse health outcomes associated with HCV and its potential as a major
driver of mortality, treating HIV/HCV coinfected patients should be a critical priority.
HIV and Liver Disease
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Although HCV co-infection accounts for much of the liver-related morbidity and
mortality in HIV-infected individuals, an excess burden of liver disease has been reported
in HIV mono-infected patients. (1) Liver enzyme elevations are frequently noted in
patients with HIV, and can not only be attributed to viral hepatitis, but also other causes
including drug-induced liver injury and both alcoholic and non-alcoholic fatty liver
disease (NAFLD). Classically, the nucleoside reverse transcriptase inhibitor
antiretrovirals (NRTIs), have been well studied for their association with hepatotoxicity,
likely due to direct toxic effect on the hepatocyte mitochondria and resultant break in the
generation of adenosine triphosphate (ATP) and accumulation of lactic acid. (4) NRTIs
cause a greater rise in lactic acid and hepatotoxicity compared to HIV protease inhibitors
(PIs), and are associated with a syndrome of hepatic steatosis. (5, 6) Among PIs, ritonavir
and ritonavir-boosted regimens have been identified as independent risk factors for the
development of hepatotoxicity. (4)
HIV-positive individuals also demonstrate a significant prevalence of NAFLD,
which is viewed as a hepatic manifestation of metabolic syndrome in the general
population. Risk factors of obesity, hypertension, insulin resistance, dyslipidemia, and
diabetes mellitus are prevalent within the HIV population as well. However, HIVinfected patients are even more prone to NAFLD due to HIV itself, viral hepatitis, or
ART toxicity. HIV itself can affect lipid profiles, with a higher viral load associated with
lower LDL cholesterol and higher triglyceride concentrations. (1) Moreover, increased
intestinal permeability through villous effacement and depletion of CD4 cells increases
the amount of bacterial lipopolysaccharide reaching the liver and upregulates
inflammation, accelerating NAFLD. (4) Exposure to ART is an independent risk factor
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for the development of NAFLD, and insulin resistance and lipodystrophy are associated
with the use of nucleoside inhibitors and other ART drugs. (4)
Impact of HCV on HIV Disease
The impact of HCV infection on the natural history of HIV progression is unclear.
Prior to the introduction of cART, there was no difference observed in progression to
AIDS, death, or decline in CD4+ count between HIV mono-infected and HIV/HCV coinfected patients. Progression to AIDS did not differ between HCV-positive patients
acquiring HIV and those with HIV infection alone. (1) However, in the current cART era,
there is some evidence suggesting that HCV co-infection may affect HIV progression. In
the Swiss HIV Cohort Study which consisted of patients receiving potent antiretroviral
therapy, HIV and HCV co-infection were associated with faster progression to AIDS and
slower CD4+ recovery than in patients with HIV alone. (7) Subsequent meta-analysis
found decreased CD4+ count recovery after 48 weeks of cART in HIV/HCV co-infected
patients compared to HIV mono-infected patients. (8) Mechanisms of impaired CD4+
count recovery may include chronic immune activation driven by HCV infection leading
to CD4+ T-cell apoptosis, suppression of CD4+ cell proliferation, and Fas-mediated
apoptosis due to HCV replication in peripheral blood mononuclear cells and lymphoid
tissue. (9)
Impact of HIV on HCV Disease
It is well-established that HIV modulates the natural history of HCV disease, and
HIV infection has been associated with higher HCV viral loads and increased risk of
chronic HCV infection. (10) In a longitudinal cohort of initially HCV mono-infected
patients, some of whom HIV seroconverted, HCV RNA levels after HIV seroconversion
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increased 58-fold over the study period, compared with an approximately threefold
increase in patients who remained HIV negative. (11) Multiple studies have documented
an association between higher HCV viral load and lower CD4 T cell count in co-infected
patients, suggesting that cellular immune responses play an important role in control of
HCV viral replication during chronic HCV infection. (9) HIV is also a prominent risk
factor for failing to spontaneously clear HCV after acute infection, likely due to the
impact of HIV infection on effective HCV specific T-cell responses. (12, 13) HIV
infection may also impair innate immune responses that affect HCV clearance through
diminished CD4+ stimulation of B-cell responses and antibody production. (9)
It is well-established that HIV accelerates progression to hepatic fibrosis and
cirrhosis in HCV co-infected patients. (14) A meta-analysis of 8 separate studies that
investigated the role of HIV in liver disease in HCV-infected patients found that coinfected patients had approximately 2 times the risk of cirrhosis diagnosed on liver
biopsy and approximately 6 times the risk of decompensated liver disease (severe liver
disease accompanied by clinical conditions including ascites, varices, or encephalopathy)
when compared with HCV mono-infected patients. (15) Another meta-analysis of 27
natural history studies found a relative risk (RR) of 1.72 of cirrhosis among patients
coinfected with HIV/HCV compared to HCV mono-infected patients. (15, 16) An
unusually rapid progression to cirrhosis was also demonstrated in a multicenter crosssectional study, where mean interval from estimated time of HCV infection to cirrhosis
was significantly longer in HIV-negative than HIV-positive patients (23.2 vs 6.9 years,
p<0.001). (17)
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Accelerated fibrosis progression in the co-infected population has also been
validated in multiple studies. In 282 HIV/HCV co-infected patients with 435 paired liver
biopsies, fibrosis progression by at least 1 METAVIR stage after 2.5 years of follow-up
was seen in 34% of the study population. (18) Two studies have demonstrated that while
the majority of HIV/HCV co-infected patients did not show evidence of histologic
progression over the course of 3 years, progression did occur in 16-24%. In a study of
174 co-infected patients, significant fibrosis defined as two Ishak units or greater between
biopsies occurred in 24% over a 3-year interval. (19) In another study, which was a
retrospective review of 135 co-infected individuals with a median time of 3.3 years (2.05.2) between repeat biopsies, 44% demonstrated fibrosis progression, with 16% having a
2+ METAVIR stage increase. (14, 19)
Mechanisms of Fibrogenesis in HIV/HCV Co-infection
Liver fibrosis occurs when extracellular matrix (ECM) deposition exceeds the rate
of ECM clearance and produces a net increase of ECM proteins that initiate the cascade
of nodule development and cirrhosis. Hepatic stellate cells (HSC) have been implicated
as the primary instigators of fibrogenesis and when activated by hepatocytes or Kupffer
cells, HSCs become myofibroblast-like cells that produce ECM and tissue inhibitors of
metalloproteinases (TIMPs) which further downregulate matrix degradation. (9)
The mechanisms associated with accelerated fibrosis progression rates (FPR)
among HIV/HCV co-infected patients may include direct viral effect on the hepatocytes
and/or stellate cells, as direct activation of HSCs via HIV gp120 leads to increased
expression and secretion of monocyte chemoattractant protein (MCP-1), a
proinflammatory cytokine and stimulant of Type 1 collagen production. (20)
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Additional mechanisms include diminished HCV-specific T cell responses,
altered levels of matrix metalloproteinases and fibrosis biomarkers, increased oxidative
stress and induction of hepatocyte apoptosis via CXCR4, HIV-associated gut depletion of
CD4 cells, and immune/cytokine dysregulation. (21, 22) Markers of microbial
translocation such as lipopolysaccharide, lipopolysaccharide binding protein, CD14, and
fucose-binding lectin are raised in co-infected individuals and show strong correlation
with HIV-related depletion of CD4+ cells and progressive HCV-related liver disease.
(23) The reduced ratio of CD4+ to CD8+ cells associated with HIV infection may also
play a role because CD8+ cells are more fibrogenic than CD4+ cells. (24) HIV/HCV coinfected patients have increased intrahepatic IFN-gamma and TNF-alpha levels with
higher IFN-gamma mRNA levels, which correlate with higher levels of fibrosis. (25)
Moreover, HIV has been shown to accentuate an HCV-driven pro-fibrogenic program in
hepatocyte and HSC lines through reactive oxygen species (ROS), NFkB, and TGFB1
upregulation. (26)
Increased risk of decompensation, mortality, and HCC
Several studies have demonstrated an association between HIV/HCV coinfection
and elevated rates of hepatic decompensation and mortality. One meta-analysis found an
adjusted RR of 6.14 for decompensated cirrhosis, and similar increases in RR were found
in a recent study where the incidence of decompensated cirrhosis was 7.4% compared to
4.8% (p<.001) at 10 years in HIV/HCV co-infected compared to HIV mono-infected
patients. (27, 28) There is also a significant increase in the risk of liver-related and allcause mortality in the co-infected population. In one study, mortality rates were higher in
HIV/HCV co-infected patients with 1-year, 2-year, and 5-year survival estimates of 54,
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40, and 25%, respectively, compared with 74, 61, and 44% in HCV mono-infected
patients, highlighting that co-infection reduces the survival of patients with HCV-related
end-stage liver disease and should be taken into consideration when establishing
appropriate timing of liver transplantation. (29) The prevalence of HCC is also increased
in HIV/HCV co-infection compared to HCV mono-infection, and HCC is estimated to
occur after an average of 17.8 years compared with 28.1 years in HCV mono-infection.
(30, 31)
Factors affecting Fibrosis Progression
Recent studies have begun to examine the factors affecting fibrosis progression in
the co-infected population. A multivariate analysis identified 4 independent predictors of
progression to cirrhosis in HIV/HCV co-infected patients: absence of PI therapy, heavy
alcohol consumption, low CD4 count, and age at HCV acquisition. (32) Poorly controlled
HIV mono-infection has also been found to be an independent risk factor for liver
fibrosis. (10, 33) Another study found that fibrosis progression correlated with HIV RNA
levels in a HIV/HCV co-infected population, further supporting the direct role of HIV in
liver fibrogenesis. (34)
Co-infected patients with undetectable HIV RNA through ART, in one study, had
a slower fibrosis progression rate (FPR) than those with any detectable HIV RNA level
and a FPR similar to HCV mono-infected patients, suggesting that HIV viremia and not
CD4 cell count independently predicted FPR. (35) However, not all studies have
supported a definitive role of poorly controlled HIV as indicated by viral load and CD4
count in fibrosis progression. In a prospective cohort of 184 HIV/HCV co-infected
individuals in which 24% demonstrated significant fibrosis progression over 3 years by
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liver biopsy, measures of HIV disease and its treatment (CD4 cell count, HIV-RNA level,
and ART exposure) were not significantly different compared to non-progressors. (19)
After multivariate adjustment, only the serum AST level between biopsies was
significantly associated with fibrosis progression, while covariates such as age, sex, race,
HCV-RNA level, HCV genotype, ART, HCV therapy, CD4 cell count, and HIV-RNA
level were not significantly associated with fibrosis progression.
The accelerated fibrogenesis seen in HIV/HCV co-infection may be partially
mitigated by ART. In an analysis of 2646 co-infected patients, the relative risk for
cirrhosis for those not receiving ART was 2.49 (95% CI, 1.81-3.42), compared to 1.72
(95% CI, 1.06-2.80) for those receiving ART, suggesting a protective but incomplete
effect of ART on HCV-associated liver disease. (15) Another study found similar
progression on liver histology between co-infected and HCV mono-infected patients
where most patients were on effective ART, suggesting the benefits of ART on
progression of HCV. (36) It is possible that HIV virologic suppression through ART
lessens fibrogenic pathways through reductions in CD8+ T-cell activation. (37)
Spontaneous clearance of HCV infection has been described occasionally in coinfected patients with the IL28B CC genotype after initiating antiretroviral therapy and
regaining immune competence. (13) Antiretroviral therapy interruption has also been
found to be associated with increased risk of liver fibrosis progression in HIV/HCV coinfected patients, with a hazard ratio for ART interruption of 2.52 (95% Confidence
Interval [CI] 1.20-5.28). (38)
The type of antiretroviral therapy may also play a role in modulating fibrogenesis.
Recent studies have reported conflicting findings about the impact of protease inhibitor
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(PI)- based therapy on fibrosis progression—one study reported that the use of PI-based
ART in HIV/HCV co-infected patients was associated with less severe fibrosis and
slower fibrosis progression, while another study found that the use of protease inhibitors,
mainly lopinavir, was associated with increased liver fibrosis progression. (39, 40)
Fibrosis progression in co-infected persons may be influenced to a greater degree by the
antiretroviral therapy backbone more so than the class of anchor agent, as both PI- and
NNRTI-based regimens were associated with increases in APRI score, another measure
of hepatic fibrosis, over time when combined with abacavir/lamivudine (ABC/3TC). (41)
The presence of metabolic derangements such as obesity, diabetes, and
hyperlipidemia may also accelerate the progression to advanced fibrosis in the coinfected population by generating a proinflammatory and high oxidative stress
environment. Steatosis is a frequent histologic finding among patients with chronic
Hepatitis C infection, and is significantly associated with body mass index as well as
fibrosis. Thus, increasing body mass index (BMI) may play a role in the pathogenesis of
steatosis in chronic Hepatitis C infection, and steatosis may contribute to fibrosis. (42)
Insulin resistance and type 2 diabetes are also tightly linked to severe fibrosis, likely due
to the ability of insulin to stimulate hepatic stellate cells and induce tumor necrosis-factor
alpha and connective growth factor production. (43, 44) Moreover, hyperglycemia leads
to enhanced formation and deposition of advanced glycation products that activate
hepatic stellate cells, which may induce liver collagen production and upregulation of
pro-fibrogenic cytokines. (44) In a cohort of patients with genotype 1 chronic HCV
infection, not only was the presence of insulin resistance linked to advanced fibrosis, but
overt type 2 diabetes also further increased the risk of severe fibrosis. (45) Diabetes has
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been associated with a 2-3 fold increase in the risk of HCC, regardless of the presence of
HCV, HBV, alcoholic liver disease, or non-specific cirrhosis. (46) Dyslipidemia may also
be an important risk factor, as low HDL and diabetes were significantly associated with
development of cirrhosis in a cohort of co-infected veterans. (47)
A growing body of evidence suggests that the concurrent use of statins, 3hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors, in HIV/HCV
co-infected patients may slow fibrosis progression due to their anti-inflammatory,
immunomodulatory, and antineoplastic properties. In animal models, statins have
demonstrated antifibrogenic effects by blocking the activation of hepatic myofibroblasts
and preventing proliferation of hepatic stellate cells and collagen production. (48) Recent
studies have reported an association between statin use and reduced risk of cirrhosis and
HCC in the HCV mono-infected population. (48-50) In a large cohort of HIV/HCV coinfected veterans, statin use >= 30% time was significantly associated with reduced risk
of development of cirrhosis compared with those with less time on statin drugs. (47)
Therefore, the benefits of statin use may extend beyond its cardioprotective properties to
include reduction in cirrhosis progression in patients with chronic liver disease.
Prior treatment with interferon-based therapy may also play a role in fibrosis
progression. The antifibrotic effects of interferon α may be due to repression of the
collagen gene (COL1A2) promoter sequence and collagen gene transcription. (51) A
study of 74 co-infected patients found that those that received Pegylated-Interferon α-2a
based therapy demonstrated significant decreases in fibrosis progression rate (FPR) and
stabilization or regression of cirrhosis compared to those who received no treatment or
interferon-based therapy. (52) Moreover, Peg-IFN α-2a/RBV therapy improved hepatic
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histology and led to a decrease in fibrosis progression not only in patients who achieved
sustained virologic response (SVR) but also in non-responders, suggesting that the
benefits of treatment with Peg-IFN α-2a/RBV may extend beyond viral clearance to
histologic improvement and delayed fibrosis progression.
The order of acquisition of HIV and HCV may be an important consideration.
Historically, most co-infected patients acquired HCV first through parenteral routes and
then subsequently became infected with HIV. This order of infection is the rule in
patients with parenteral exposures because HCV is much more infectious than HIV via
parenteral routes. (53) However, this paradigm has shifted in recent years with an
emerging epidemic of sexually acquired HCV infection among HIV-infected men who
have sex with men (MSM), where the order of infection is reversed because HIV is more
infectious than HCV through sexual transmission. (54) Available evidence shows that
these HIV-infected men rapidly progress to moderate levels of fibrosis within the first
year of HCV infection, and some with the most severe immunocompromise experience
further rapid progression to cirrhosis. (55) Additional prospective studies are necessary to
more clearly define the long-term outcomes of these HIV-infected men after HCV
infection.
Methods for Assessing Fibrosis Progression
The accurate evaluation of severity of liver fibrosis in chronic hepatitis C is
critical for determining therapeutic indications and prognosis. Among the available
methods for assessing liver fibrosis, liver biopsy is currently considered the gold standard
but its use is limited by cost, invasiveness, and potential complications such as pain,
bleeding, peritonitis, and bowel perforation. Due to limited sampling of the liver
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parenchyma, liver biopsy is demonstrated to carry a diagnostic error rate of 20% for
fibrosis stage. (56) Increasingly, non-invasive tools such as serologic-based scores are
being utilized, including the AST-to-platelet ratio (APRI), FIB-4, FibroTest, FibroSpect
II, HepaScore, as well as imaging-based methods such as vibration controlled liver
elastography. However, routine use of many of these noninvasive tests can still be
hampered by cost, false negative or positive results, or the need for standardization
assays.
FIB-4, the assessment tool used in this study, is a simple index which was
specifically developed in 832 co-infected patients enrolled in the AIDS Pegasys Ribavirin
International Coinfection Trial (APRICOT). In many respects, the FIB-4 serves as a
highly useful clinical tool—it is based on simple calculations and easy to use, results are
available in a timely fashion, and it is inexpensive, relying only on readily available clinic
parameters such as age, ALT, AST, and platelet count without additional costs for
equipment. FIB-4 <1.45 was associated with a sensitivity of 70% and a NPV of 90% to
exclude advanced fibrosis, while a score >3.25 had a specificity of 97%, and a PPV of
65%. Values between 1.45 to 3.25 were classified as indeterminate. (57)
Since the APRICOT trial, FIB-4 has subsequently been validated in multiple
studies as a simple, accurate, and inexpensive method for assessing liver fibrosis for
values outside 1.45-3.25, and shows promise for application in emerging countries where
more expensive and invasive methods of assessing fibrosis are not accessible. (58-60)
Moreover, it is not only predictive of advanced fibrosis, but also of liver-related clinical
outcomes and overall mortality. (61, 62)
Treatment of HIV/HCV Co-Infection
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For many years, the standard therapy for treatment of chronic hepatitis C has been
pegylated interferon α (Peg-IFN) and ribavirin (RBV), administered for 24- to 48-weeks
depending on the genotype. Under this regimen, viral eradication rates were suboptimal.
In patients with genotype 1 HCV, sustained virologic response (SVR) rates were 40%
following 48 weeks of Peg-IFN/RBV and even lower in those with African descent, HIV
co-infection, or high viral loads or advanced fibrosis. (63-65) In addition, significant side
effects associated with interferon and ribavirin therapy have also hindered patient
tolerance. Interferon treatment is associated with myelosuppression, flu-like symptoms,
neuropsychiatric symptoms, and also lowers the seizure threshold and exacerbates
immune-mediated conditions. (66) The addition of ribavirin confers additional risks of
hemolytic anemia, rash, and insomnia.
However, the advent of revolutionary new interferon-free direct-acting antiviral
agents (DAA) has radically changed the face of HCV therapy. DAAs are designed to
inhibit viral proteins involved in the HCV life cycle, with numerous potential targets such
as the NS3/4A serine protease, NS5A replication complex protein, NS5B RNAdependent RNA polymerase, and NS4B and NS3 helicase proteins. (67) With the
proliferation of DAAs that offer the potential of highly effective and well-tolerated
treatment, regimen selection varies depending on patient genotype and factors such as the
presence of cirrhosis and prior treatment history.
In contrast to the previous paradigm in the interferon era, the DAA era has seen
comparable HCV cure rates of over 90% in HIV/HCV co-infected patients, eliminating
the need for distinguishing between mono- and co-infected patients. (68) The efficacy of
DAAs was first demonstrated in trials of the protease inhibitors telaprevir and boceprevir

14

added to peginterferon and ribavirin, and further confirmed in trials of the newer DAAs,
even with regimens that do not contain interferon. It is notable, however, that most
clinical trial data on the efficacy of HCV therapy derives from patients on antiretroviral
therapy with suppressed HIV viral loads and CD4 counts greater than 200 cells/mm3 and
may lack generalizability in the real world. (69-74) Thus, curative all-oral treatment is a
possibility for all HIV/HCV co-infected patients.
A major consideration is monitoring drug-drug interactions between antiretroviral
therapy and DAAs. For example, because ledipasvir (an NS5a inhibitor) and sofosbuvir
(an NS5b inhibitor) are both substrates of the P-glycoprotein transporter, concomitant use
of ritonavir boosted tipranavir is not recommended because it may decrease levels due to
induction of the transporter. Simeprevir (HCV protease inhibitor) is oxidatively
metabolized by the CYP3A subfamily and not recommended for use with HIV protease
inhibitors boosted by ritonavir. (75)
Theoretically, all patients with virologic evidence of chronic HCV infection
should be considered for treatment; however, there are clinical characteristics that are
taken into account when deciding when to initiate HCV therapy. Per the American
Association of the Study of Liver Diseases (AASLD) and Infectious Disease Society of
America (IDSA) guidelines, treatment should not be withheld from those who currently
use illicit drugs or those who are in an opioid treatment program, provided that they wish
to be treated, are willing and able to maintain close monitoring, and practice
contraception; however, many healthcare providers remain reluctant to treat this at-risk
population. (76) Although history of alcohol abuse is not an absolute contraindication to
treatment, continued alcohol use has been shown to decrease the response to interferon-
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based therapy and accelerate disease progression. (77, 78) Limited data is available on
the effectiveness of DAAs in patients who continue to drink.
Financial constraints continue to prevent the widespread availability of novel
DAA regimens. Sofosbuvir is an example of a new oral HCV medication that, when
combined with other therapies, has a therapeutic efficacy (cure) greater than 90% across
4 genotypes, limited adverse effects, and a shorter treatment window than its interferonbased predecessors; however, its cost forces payers to ration this lifesaving treatment.
One study in Massachusetts found that the mean drug cost per patient per SVR was
$123,559 for ledipasvir/sofosbuvir and $251,550 for sofosbuvir + simeprevir. (79) It is
estimated that third-party payers would need $136 billion to cover medication costs for
all eligible patients with HCV from 2015-2020, of which $61 billion would need to be
paid by the government. (80) For this reason, some payers restrict access only to patients
in more advanced stages of disease, in some cases requiring fibrosis scores of F3 or F4
before covering a DAA medication. (81) In addition, many prior authorization criteria
require abstinence from the use of alcohol, illicit drugs, or both in the months leading up
to treatment approval, presenting another barrier to treatment. The immense budgetary
impact on private and government providers that would be incurred from treating all
eligible patients with HCV in the United States continues to preclude widespread access
to treatment, making knowledge of the factors that predict fibrosis progression in the
HIV/HCV co-infected population all the more critical for effective resource allocation.
Current guidelines suggest a high priority for treating the HIV/HCV co-infected
population given the more rapid progression to advanced liver disease in the setting of
HIV infection. (82) Achieving SVR has been associated with improved overall survival
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in co-infected patients even in lower stages of fibrosis (F0-F2), suggesting that HCV
therapy may provide benefits beyond the cure of HCV and may prevent the progression
of liver disease. (83) However, it seems reasonable to adopt a “wait and see” policy for
patients with little or no fibrosis (F0-F1) since they are unlikely to progress while taking
stable cART, while for patients with advanced fibrosis, treatment should be prioritized
because fibrosis has already developed and cirrhosis may occur. (68) Therefore,
determination of the presence of significant fibrosis or liver cirrhosis is vital for resource
allocation and treatment prioritization purposes. As a corollary, predicting who is likely
to progress would be important for resource allocation as well. Finally, longitudinal
natural history studies in an established cohort are uncommon, but provide critical
information about the time course of illness and fibrosis progression in the HIV/HCV coinfected population.

Hypothesis/Aims:
The purpose of this study is to elucidate the natural history and identify potential
predictors of fibrosis progression in the HIV/HCV co-infected population. We
hypothesized that in our co-infected cohort, elevated BMI, history of alcohol abuse, low
CD4 count, and elevated HIV viral load would be associated with faster fibrosis
progression. We analyzed data collected retrospectively and examined (a) patient
demographics and clinical characteristics within this group of patients; (b), the noninvasive score FIB-4 in order to describe patterns of fibrosis progression over 5 years;
and (c), the association of various factors such as BMI, diabetes, hyperlipidemia, history
of alcohol abuse, CD4 count, and HIV viral load with FIB-4 progression.
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Methods:
Study subjects were selected from HIV/HCV co-infected patients receiving care
at the Nathan Smith Clinic of Yale-New Haven Hospital from June 2002 through April
2016. The date of study entry was the date of last laboratory values prior to treatment
with DAAs or the most recent laboratory values for patients not treated with DAAs. Data
going back 5 years was chosen because a 5-year time interval has been postulated as the
average time to progression between stages of liver fibrosis. Patients who did not have
cirrhosis (as defined by FIB-4>3.25) at 5 years prior to study entry were eligible for the
study.
On a retrospective review of medical records, data on the following variables
were collected: demographics such as gender and race, clinical characteristics related to
HCV and HIV such as year of HIV and HCV diagnosis as recorded in chart notes (if
known), mode of HCV acquisition, HCV genotype, antiretroviral therapy type and
backbone, prior treatment for HCV with interferon-based therapy, liver biopsy stage if
performed, and DAA treatment course if treated. The body mass index (BMI) used in the
analysis was the value recorded closest to the date of study entry. Diagnosis of diabetes
was based on the presence of diabetes mellitus on the patient’s problem list, or at least 2
Hemoglobin A1c values ≥ 6.5. Diagnosis of hyperlipidemia was captured as charted in
patients’ medical record, or at least 2 values of elevated total cholesterol over the
previous 5 years. Statin use was recorded if a statin was on the patient’s medication list at
the time of study entry. History of smoking was positive if the patient was a current or
former smoker as recorded in clinic notes at the time of study entry. The Alcohol Use
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Disorders Identification Test (AUDIT)- C score was recorded as the highest AUDIT-C
score recorded at a patient visit during the 5 years prior to study entry; the AUDIT-C
score is routinely calculated at each clinic visit, with scores of 4 or more in men and 3 or
more in women considered a positive screen and optimal for identifying hazardous
drinking or active alcohol use disorders. History of alcohol abuse was determined by any
prior history of alcohol abuse recorded in visit notes. Active drug use was determined as
documented in visit notes or positive urine toxicology screen for cocaine or opiates
within the previous 6 months before study entry. Hepatitis B co-infection was indicated
by positive Hepatitis B surface antigen (HBsAg). The VACS score (Veterans Aging
Cohort Study) at time of study entry was calculated using the patient’s age, sex, race,
CD4 count, HIV viral load, hemoglobin, AST, ALT, platelet count, FIB-4, Creatinine,
eGFR, and Hepatitis C status at the time of study entry, using the calculator provided at
https://vacs.med.yale.edu/calculator/IC. VACS scores typically range from 0 to 100, with
a higher score indicating worse prognosis and increased risk of mortality.
Routine laboratory values including AST, ALT and platelet count were extracted
to calculate the FIB-4 score, which is computed as follows: FIB-4 = age [years] × AST
[IU/L]/platelet count [platelets ×109/L] × (ALT1/2[IU/L]). Yearly FIB-4 scores dating
back 5 years were calculated from the last FIB-4 prior to treatment initiation for patients
treated with DAAs, or the most recent FIB-4 for patients not treated with DAAs. The
mean of 3 values closest to the chosen time point was used to calculate the annual FIB-4
score. The closest CD4 count, CD4/CD8 ratio, HIV viral load, and HCV viral load
obtained within 6 months of the annual FIB-4 score was recorded. In order to obtain 3
year and 5 year log viral loads and CD4 counts, all log viral loads or CD4 counts for each
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patient over the 3 year or 5 year period prior to study entry were extracted and the mean
of all the available values was obtained.
The primary outcome measure of the study was progression to advanced fibrosis,
indicated by FIB-4 levels exceeding the value of 3.25, and patients were categorized
based on FIB-4 progression over the course of 5 years. Progressors were defined as those
whose FIB-4 progressed from below 3.25 to above 3.25 while non-progressors were
defined as those whose FIB-4 remained below 3.25. Descriptive statistics were used to
assess baseline characteristics. In order to compare progressors vs non-progressors,
parametric (t-tests) or non-parametric (Wilcoxon scores) methods were used for
continuous variables as appropriate; Chi-square or Fisher’s exact test were used for
categorical variables as appropriate. Univariate logistic regression models were used to
examine factors associated with progression to FIB-4 >3.25: such models were used for
age, BMI, diabetes, hyperlipidemia, statin use, alcohol abuse, injection drug use, HIV
viral load, CD4+ cell count, among others. Variables were chosen for inclusion in a
multivariable model based on a univariate model p-value of ≤ 0.20. A p value less than
0.05 was considered statistically significant. Statistical analysis was performed using
SAS v9.4 (SAS Institute Inc., Cary, NC). The Yale University Institutional Review Board
approved the study protocol.

Results:
Patient Demographics
Of 126 HIV/HCV co-infected patients, 93 started out with initial FIB-4 scores
below 3.25, indicating lack of advanced fibrosis. This subgroup of 65 males and 28
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females had mean age of 56.7 years and average BMI of 27.1; 32.3% were white, 53.8%
were black, 11.8% identified as Hispanic (Table 1). 15.0% of patients had diabetes,
22.6% had a history of hypercholesterolemia, and 17.2% were prescribed a statin. 90.3%
were current or former smokers, and 25% demonstrated active drug use. 50.5% of
patients had documented history of alcohol abuse within the chart. The mean AUDIT-C
score was 1.1 and 56.0% had an AUDIT-C score of 0. The mean VACS score was 38.5,
corresponding to a 5-year mortality rate of approximately 18%, and only 2 patients were
also co-infected with hepatitis B.
Table 1. Baseline characteristics of 93 HIV/HCV co-infected patients
Characteristic
Age, mean years
Gender
Male
Female
Race
White
Black
Hispanic
Other
Body mass index, mean kg/m2
History of diabetes
History of hyperlipidemia
Statin use
Ever smoker
History of alcohol abuse
Active drug use
AUDIT-C Score (highest recorded)
0-3
4+
VACS Index Score, mean (range)1
Hepatitis B co-infection

Total (N=93)
56.7
65 (69.9%)
28 (30.1%)

30 (32.3%)
50 (53.8%)
11 (11.8%)
2 (2.2%)
27.1
14 (15.1%)
21 (22.6%)
16 (17.2%)
84 (90.3%)
46 (49.5%)
23 (25.0%)
80 (87.9%)
13 (12.1%)
38.5 (5-107)
2 (2.2%)

AUDIT, Alcohol Use Disorders Identification Test; VACS, Veterans Aging Cohort Study
1. The VACS score ranges from 0-164, with higher scores predicting higher risk of 5 year mortality.
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HCV-Specific Characteristics
Injection drug use was the predominant risk factor for HCV acquisition (63.4%),
followed by both injection drug use and heterosexual transmission (12.9%), heterosexual
transmission alone (6.5%), and men who have sex with men (MSM) (3.2%) (Table 2).
The duration of HCV infection was available for 27 patients and the mean was 19.8
years. Genotypes included: genotype 1 (81.2%), genotype 3 (9.4%), genotype 2 (5.9%)
and genotype 4 (3.5%). 15 patients (16.1%) had prior treatment with interferon-based
therapy. Of 38 patients who had ever received a liver biopsy, 47.4% (18) showed no to
mild fibrosis (F0-F1), 36.8% (14) showed moderate fibrosis (F2), 7.9% (3) showed
severe fibrosis (F3), and 7.9% (3) showed evidence of cirrhosis (F4). Of the three patients
with biopsy proven cirrhosis, FIB-4 showed concordance with liver biopsy in two
patients.
52 patients were subsequently treated with DAAs while 41 remained untreated at
the time of data collection. Of those treated with DAAs, the majority (65.4%) were
treated with ledipasvir/sofosbuvir, 15.4% were treated with sofosbuvir/ribavirin, 9.6%
with sofosbuvir/simeprevir, 7.7% with sofosbuvir/daclatasvir, and 1.9% with other
regimens.

Table 2. HCV-Specific Characteristics
HCV-Specific Characteristic
Risk mode of HCV acquisition
IDU alone
IDU and heterosexual
Heterosexual
MSM
Blood Transfusion
IVDU, heterosexual,

Total (N=93)
59 (63.4%)
12 (12.9%)
6 (6.5%)
3 (3.2%)
3 (3.2%)
1 (1.1%)
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tattoos, blood transfusion
Unknown
Duration of HCV infection, mean years1
HCV Genotype
1
2
3
4
Liver biopsy performed
F0-1
F2
F3
F4
Subsequent treatment with DAA
DAA treatment regimen:
Ledipasvir/sofosbuvir
Sofosbuvir/ribavirin
Sofosbuvir/simeprevir
Sofosbuvir/daclatasvir
Elbasvir/grazoprevir

12 (12.9%)
19.8
69 (81.2%)
5 (5.9%)
8 (9.4%)
3 (3.5%)
38 (40.9%)
12
14
3
3
52 (55.9%)
34
8
5
4
1

1.Data on year of HCV diagnosis available in 27 patients

HIV-Specific Characteristics
The mean duration of HIV infection based on year of HIV diagnosis was
available for 82 patients and was 22.3 years (Table 3). At the time of study entry, the
median CD4 count was 564 cells/mm3 (Interquartile Range [IQR] 368, 891) the median
CD4/CD8 ratio was 0.7 (IQR 0.4, 1.1), and the median historical nadir CD4 count was
308 cells/mm3 (IQR 186, 498). The majority (88.4%) had HIV viral loads <500
copies/mL.
The vast majority of patients (97.9%) were on antiretroviral therapy; 29% were on
a protease inhibitor-based regimen, 28.0% were on a non-nucleoside reverse transcriptase
inhibitor (NNRTI)- based regimen, and 28.0% were on an integrase strand transfer
inhibitor (INSTI)-based regimen. The antiretroviral regimen backbone consisted of
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 67.7%, and
abacavir/lamivudine (ABC/3TC) for 20.4%.
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Table 3. HIV-Specific Characteristics
HIV-Specific Characteristic
Duration of HIV infection, mean years
CD4+ Cell count, median (IQR)
CD4/CD8 ratio, median (IQR)
Nadir CD4+ count, median (IQR)
HIV-1 RNA <500 copies/mL at study entry
n (%)
On ART n (%)
ART treatment regimen (n):
PI-based
NNRTI-based
INSTI-based
(INSTI and PI) NRTI sparing
Other1
ART backbone (n):
TDF/FTC
ABC/3TC
Other
1.

Total (N=93)
22.3
564 (368, 891)
0.7 (0.4, 1.1)
308 (186, 498)
76 (88.4%)
91 (97.9%)
27
26
26
4
8
63
19
9

Other regimens included: raltegravir(RAL)/tenofovir disoproxil
fumarate(TDF)/emtricitabine(FTC)/darunavir(DRV)/ritonavir(r) (3),
TDF/FTC/DRV/r/DTG(dolutegravir), RAL/3TC/ATZ(atazanavir)/r, RAL/TDF/FTC/ATZ/r,
RPV(rilpivirine)/TDF/FTC/DRV/c(cobicistat), RAL/TDF/FTC/ETR(etravirine)/DRV/r

Progression to Advanced Fibrosis
Over the course of 5 years, 68 patients (73.1%) had FIB-4 remain below 3.25,
while 25 (26.9%) had FIB-4 progress to >3.25 (Table 4, Figure 1). Of the 68 nonprogressors, 23 patients started out below 1.45, and 14 remained below 1.45 after 5 years.
Five years prior to study entry, the annual mean FIB-4 score of the full cohort started at
1.93, trending upward to 2.07 at 4 years, 2.25 at 3 years, 2.37 at 2 years, 2.46 at 1 year,
and 2.44 at the time of study entry. In patients whose FIB-4 remained below 3.25 (nonprogressors), the mean annual FIB-4 scores from 5 years to time of study entry were 1.73,
1.81, 1.82, 1.88, 1.91, and 1.73. In patients whose FIB-4 progressed to above 3.25
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(progressors), the mean annual FIB-4 scores from 5 years to time of study entry were
2.49, 2.91, 3.31, 3.77, 3.88 and 4.37. The difference between lowest and highest FIB-4
scores was 1.39 in progressors and 0.18 in non-progressors.

Table 4. Trends in FIB-4 Progression over 5 years
Total
(N=93)

Progressed
to >3.25
Remained
<3.25

Mean (SD)
FIB-4 5
years prior
t = -5

25
2.49 (0.51)
(26.9%)
68
1.73 (0.63)
(73.1%)

Mean
(SD) FIB4 4 years
t = -4

Mean (SD)
FIB-4 3
years
t = -3

Mean
(SD) FIB4 2 years
t = -2

2.91
(1.00)
1.81
(0.84)

3.31 (1.51) 3.77
(1.69)
1.82 (0.74) 1.88
(0.71)

Mean
(SD)
FIB-4 1
year
t = -1
3.88
(1.76)
1.91
(0.83)

Mean FIB-4
(SD) at time
0
t=0
4.37 (0.81)
1.73 (0.57)

Figure 1. FIB-4 Progression Over 5 Years
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Comparison of Progressors to Non-Progressors
We hypothesized that markers of HIV and HCV disease severity such as duration
of disease and quantitative markers would differ between progressors and nonprogressors. Duration of HIV and HCV infection (when available), mean HIV and HCV
viral load, nadir CD4 count, CD4 count, and CD4/8 ratio (over the 3 or 5 years prior to
study entry) did not differ significantly between patients who progressed to >3.25 and
patients who remained <3.25 (Table 5).

Table 5. Correlates of Fibrosis Progression
Characteristic
HCV duration, years
(*N=27)
HIV duration, years (N =
82)
Mean log HCV viral load
(from t= 0 to t=-3)
Mean log HCV viral load
(from t=0 to t=-5)
Mean log HIV viral load
(from t=0 to t=-3)
Mean log HIV viral load
(from t=0 to t=-5)
Mean CD4 count (from t=0
to t=-3)
Mean CD4 count (from t=0
to t=-5)
Mean CD4/CD8 ratio
(from t=0 to t=-3)
Mean CD4/CD8 ratio
(from t=0 to t=-5)
1.

Non-progressors (N = 68)
Mean +/- S.D.
20.0 +/- 8.9

Progressors (N = 25)
Mean +/- S.D.
19.0 +/-12.5

P value1

22.6 +/- 6.6

21.4 +/- 8.4

0.51

6.3 +/- 1.1

5.7 +/- 1.0

0.02

6.3 +/- 1.1

5.9 +/- 1.1

0.08

2.0 +/- 0.7

2.2 +/- 0.9

0.14

2.0 +/- 0.6

2.2 +/- 0.8

0.21

633 +/- 342

551 +/-336

0.31

618 +/- 336

550 +/- 323

0.38

0.7 +/- 0.5

0.9 +/-0.7

0.22

0.7 +/- 0.4

0.9 +/- 0.7

0.13

P values were obtained from t-tests or the Wilcoxon Two-Sample test (non-parametric) as
appropriate.

0.95
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Predictors of Fibrosis Progression
In univariate logistic regression models, age, gender, race, BMI, alcohol abuse,
active injection drug use, diabetes, hyperlipidemia, statin use, HIV and HCV duration and
viral load, and CD4 count did not significantly predict progression to advanced fibrosis
(Table 6). A number of variables were suggestive of a protective trend (such as
hyperlipidemia, statin use, AUDIT score <4, HIV viral load <500 copies/mL), however,
they did not achieve statistical significance. Similarly, the use of non-NNRTI-based
regimen appeared protective but was not statistically significant. The 3 year mean log
HCV viral load (defined as the mean log HCV viral load in the 3 years prior to study
entry for whom data was available) showed a statistically significant effect favoring low
HCV viral loads predictive of fibrosis progression. Conversely, a CD4 count <100
cells/mL at the time of study entry appeared to correlate with higher risk of progression,
but this was not statistically significant.
In a multivariable logistic regression model, age, race, gender, CD4 count, viral
load, hemoglobin, and estimated glomerular filtration rate (eGFR) were not found to be
significant, in addition to AUDIT score, ART class or backbone, statin use, and 3 year
mean HIV viral load (Table 7).

Table 6. Univariate Analysis of Correlates of Fibrosis Progression
Demographic characteristic

Age
Female vs male
Black vs non-black
BMI <18.5 vs >=30 kg/m2
BMI 18.5-<25 vs >=30 kg/m2

Odds Ratio >1 (95%
CI)
‘Elevated’ Risk
1.01 (0.94, 1.08)
1.13 (0.42, 3.04)

Odds Ratio <1 (95%
CI)
‘Reduced’ Risk

0.73 (0.29, 1.83)
1.91 (0.26, 13.87)
1.43 (0.48, 4.24)
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BMI 25-29 vs >=30 kg/m2
Comorbid conditions
History of alcohol abuse
Active drug use
Diabetes
Hyperlipidemia
Statin use
Ever smoker
AUDIT score <4 vs 4+
HIV-specific characteristic
PI-based ART
Non-NNRTI based ART
ABC/3TC ART
HIV duration in years
HIV viral load <500 vs >=100,000
copies/mL at study entry
HIV viral load 500-9999 vs
>=100,000 copies/mL at study
entry
3-year mean log HIV viral load
5-year mean log HIV viral load
CD4 count <100 vs >=500 cells/mL
at study entry
CD4 count 100-199 vs >=500
cells/mL at study entry
CD4 count 200-349 vs >=500
cells/mL at study entry
CD4 count 350-500 vs >=500
cells/mL at study entry
3-year mean CD4/CD8 ratio
5-year mean CD4/CD8 ratio
HCV-specific characteristic
HCV duration in years
HCV duration, <10 vs 10+ years
3-year mean log HCV viral load
5-year mean log HCV viral load
Prior HCV treatment

0.45 (0.10, 2.00)
0.92 (0.37, 2.31)
0.93 (0.32, 2.71)
1.64 (0.49, 5.47)
0.57 (0.17, 1.90)
0.34 (0.07, 1.60)
0.71 (0.16, 3.08)
0.59 (0.12, 2.93)
1.21 (0.45, 3.28)
0.56 (0.19, 1.69)
1.34 (0.45, 4.01)
0.98 (0.91, 1.05)
0.36 (0.05, 2.71)
0.50 (0.02, 11.09)

1.52 (0.86, 2.68)
1.48 (0.79, 2.79)
6.91 (0.57, 83.5)
3.46 (0.61, 19.59)
1.48 (0.33, 6.70)
1.15 (0.34, 3.88)
1.66 (0.73, 3.76)
1.96 (0.81, 4.76)
0.99 (0.89, 1.10)
0.15 (0.02, 1.50)
0.62 (0.38, 1.00)
0.70 (0.46, 1.08)
1.45 (0.44, 4.76)

For continuous variables, the odds ratio refers to the per unit increase in risk.

Table 7. Multivariate Analysis of Correlates of Fibrosis Progression
Demographic Characteristic
Age
Female sex

Odds Ratio (95% CI)
0.99 (0.90, 1.09)
0.80 (0.20, 3.13)
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Black race
Comorbid conditions
AUDIT-C score level
Statin use
Hemoglobin <10 vs >=14 g/dL
Hemoglobin 10-11.9 vs >14 g/dL
Hemoglobin 12-13.9 vs >=14 g/dL
eGFR <30 vs >=60 mL/min
eGFR 30-44.9 vs >=60 mL/min
eGFR 45-59.9 vs >=60 mL/min
HIV-specific characteristics
CD4 count <100 vs >=500 cells/mL at study entry
CD4 count 100-199 vs >=500 cells/mL at study entry
CD4 count 200-349 vs >=500 cells/mL at study entry
CD4 count 350-500 vs >=500 cells/mL at study entry
Log HIV viral load at study entry
3-year mean log HIV viral load
PI-based ART
Non-NNRTI based ART
ABC/3TC ART
HCV-specific characteristics
Prior HCV treatment with interferon

1.03 (0.28, 3.72)
0.53 (0.10, 2.71)
0.40 (0.08, 1.96)
1.85 (0.04, 87.17)
1.14 (0.19, 6.80)
3.11 (0.89, 10.82)
1.47 (0.07, 31.61)
6.40 (0.65, 63.49)
3.71 (0.69, 19.90)
19.01 (0.28, 1000)
12.13 (0.67, 221.30)
1.40 (0.22, 8.86)
0.92 (0.21, 3.99)
0.72 (0.29, 1.82)
1.50 (0.85, 2.66)
1.01 (0.34, 3.01)
0.52 (0.15, 1.82)
0.98 (0.30, 3.23)
1.67 (0.49, 5.71)

Discussion:
Patients with chronic hepatitis C and HIV co-infection exhibit more rapid
progression to advanced liver disease, making coinfection a compelling reason to
prioritize a patient for HCV antiviral therapy, particularly in the era of highly effective
and well-tolerated DAAs. However, in the current era, DAAs are not widely accessible
for those in need due to prohibitive costs and resource constraints, making the
prioritization of patients at greatest risk of fibrosis progression an important
consideration.
In this study of 93 HIV/HCV co-infected patients without baseline advanced
fibrosis based on FIB-4, we found that 26.9% progressed to advanced fibrosis over 5
years of follow-up. This observed incidence of fibrosis progression over a relatively short
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interval is consistent with prior studies of HIV/HCV co-infected patients where
progression to advanced fibrosis also occurred in as few as 3 to 5 years. (14, 18, 84)
Fibrosis progression of two Ishak fibrosis stages has been observed in only 8-12%
of HCV mono-infected patients over median intervals of 30-44 months, and a recent
study of nearly 14,000 HIV-infected patients found that 10% of HIV mono-infected
patients progressed to advanced fibrosis compared to 24% of HCV co-infected patients in
a median of 3 years (p<0.01). (33, 85, 86) Since our patients had likely been infected with
HCV for many years prior to the study period, our findings may also suggest that fibrosis
progression in the co-infected population does not always follow a linear trajectory of
inevitable progression, necessitating serial monitoring to facilitate detection of
individuals with progressive disease prior to the onset of clinical liver disease. (18)
We did not find history of alcohol abuse, hyperlipidemia, diabetes, BMI, CD4
count, and HIV viral load to be statistically significant predictors of fibrosis progression
(Table 6), although there appeared to be an association between HIV viral load and CD4
count at time of study entry and risk of fibrosis progression. There was a consistent trend
towards increased risk of fibrosis progression with increasing viral load—HIV viral load
<500 vs >=100,000 copies/mL showed OR 0.36, and the mean log HIV viral loads over 3
years and 5 years showed OR of 1.52 and 1.48, respectively. The CD4 level at study
entry also showed an increasing OR with each decreasing level, with OR of 1.15 for 350500 vs >=500 cells/mL, OR of 1.48 for 200-349 vs >=500 cells/mL, OR of 3.46 for 100199 vs >=500 cells/mL, and OR of 6.91 for <100 vs >500 cells/mL, although these
differences did not achieve statistical significance. The evidence implicating these
variables is conflicting in the literature. In a small study of 30 co-infected patients, heavy
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alcohol consumption, metabolic disorder, CD4 count, and HIV viral load were not
significantly associated with fibrosis progression, and only elevated ALT (p<0.001) and
AST (p<.0340) higher than 3 times the upper limit of normal were associated with
fibrosis progression. (87) This was consistent with the findings of another study of 174
patients in which only the serum AST level was significantly associated with fibrosis
progression while other covariates such as age, sex, race, CD4 cell count, and HIV-RNA
did not show a significant association. (19)
In contrast, other studies have reported an association between low CD4 count
and fibrosis progression. (47, 88, 89) This was supported by increasing odds ratios for
each decreasing level of CD4 count at time of study entry in Table 6. One could assert
that the majority of our patients had clinically stable HIV infection with undetectable
HIV viral loads due to ART, making it difficult to detect any association between CD4
count and liver fibrosis progression.
We also examined the CD4/CD8 ratio because the CD4/CD8 ratio is emerging as
a biomarker of immune activation and systemic inflammation in HIV positive patients.
Our data showed that increasing CD4/CD8 ratio may have been associated with increased
risk of fibrosis progression, which was unexpected because chronic HCV infection has
been associated with low CD4/CD8 ratios in HIV positive women in a recent study. (90)
However, this same study observed low CD4/CD8 ratios in women with cleared HCV
infection, highlighting that T-cell dynamics are not well elucidated in the HIV/HCV coinfected population.
In our study, age did not predict risk of fibrosis progression, although some
studies have identified older age as an independent predictor of fibrosis progression. (91,
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92) Black race did not confer a protective effect on the development of fibrosis in our
patient population (p = 0.59), in contrast to previous findings that black race was
associated with lower rates of hepatic decompensation. (28) Despite studies reporting
improved liver histology and slower fibrosis progression rate among treated nonresponders compared to non-responders, we did not detect an effect of prior interferonbased HCV treatment on fibrosis progression in our cohort, of which 16.1% had received
prior treatment (p = 0.54). (52) AUDIT score less than 4 may have been protective (OR
0.59), though this finding was not statistically significant (0.51).
Multiple studies have supported the lack of correlation between HCV viral load
and fibrosis progression in the HCV mono-infected population (93-95) In the setting of
co-infection, HCV RNA levels increase after HIV seroconversion and continue to
increase over time compared to patients with HCV alone. (53) The level of HCV viremia
is inversely correlated with lower CD4 counts in most studies; however, overall increases
in the HCV viral load do not appear associated with severity of liver disease. (96, 97) In
our results, the 3 year mean log HCV viral load appeared to differ significantly between
progressors and non-progressors (p = 0.02, Table 5), however statistical significance was
not seen for the 5 year mean log HCV viral load (p = 0.08) and the univariate logistic
regression model showed borderline significance (p = 0.05), suggesting that any
difference in HCV viral load between progressors and non-progressors was either
confounded by other parameters or was a random chance finding.
Suppression of HIV infection through ART has been associated with slower liver
fibrosis regression rate; however, there is conflicting data regarding the impact of type of
ART on fibrosis progression. The use of protease inhibitors, mainly lopinavir, was
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associated with increased liver fibrosis progression in one study, while another reported
that PI-based ART was a protective factor against fibrosis progression. (39, 40)
Moreover, a recent study asserts that the choice of antiretroviral backbone influences
fibrosis progression more than the class of anchor agent, with abacavir/lamivudine
containing regimens associated with fibrogenesis. (41) However, we failed to find a
significant association between fibrosis progression and ART class (p = 0.70 for PI,
p=0.30 for NNRTI) or ABC/3TC backbone (p = 0.61). This could be because in our
cohort of primarily immunocompetent patients, the effect of ART on fibrogenesis may be
subtle and require observation for a duration longer than a 5 year period.
Statin therapy in HCV mono-infection has been shown to reduce cirrhosis risk by
69-87%, and recently, has also been demonstrated to mitigate the risk of liver disease
progression in HIV/HCV co-infected patients. (47, 48, 50) However, we did not find a
statistically significant association between statin use and fibrosis progression (p = 0.17)
although there seemed to be a protective trend (OR 0.34). This may be because in our
study, only a few patients (17.2%) received statin prescriptions although 22.6% had a
recorded history of hyperlipidemia. Thus, our ability to detect any protective effects
associated with statin therapy is limited. Although there are safety concerns about the
potential hepatotoxicity associated with statins, statin use in the presence of liver disease
or enzyme elevation is generally safe and well tolerated. (98) Further prospective studies
would be needed to better understand the efficacy of statin drugs as adjunct therapy in the
care of HIV/HCV co-infected patients. It is worth noting that HIV-infected patients have
a greater prevalence of dyslipidemia, earlier incidence and progression of atherosclerosis,
and a nearly twofold increased risk for myocardial infection compared to those without
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HIV, making a compelling case for increased statin use in the HIV-infected population
for cardiovascular disease prevention. (99)
We did not find a significant association between BMI, diabetes, and
hyperlipidemia and risk of fibrosis progression, in contrast to previous studies which
have identified that metabolic risk factors such as obesity, low HDL, and diabetes are
associated with development of cirrhosis. (18, 33, 47) Conversely, we found that the
diagnosis of hyperlipidemia was associated with an odds ratio of 0.57 (0.17, 1.90), which
may be attributed to the fact that of the 21 patients with hyperlipidemia, 14 were on a
statin and may have exhibited the potentially protective effects of statin treatment on
fibrosis progression. Moreover, we found that an overweight BMI in the range of 25-29
kg/m2 may have protective effects compared to the reference group with BMI of 30+ (OR
0.45), while an underweight or average BMI may have detrimental effects on fibrosis
progression compared to those with BMI of 30+. Although these results were not
statistically significant, they may support the obesity paradox in chronic disease, which
refers to an inverse association between excess adiposity and mortality. It has been
demonstrated in a group of HIV-infected men who have sex with men, where those who
were overweight possessed higher CD4 cell counts and lower viral loads than those of
normal weight (100). Prospective studies will be needed to further assess the impact of
metabolic derangements on the risk of fibrosis progression in the HIV/HCV co-infected
population.
We hypothesized that a composite score of disease severity might be predictive of
progression. The VACS Index generates a weighted score based on age, routinely
monitored indicators of HIV disease (CD4 count and HIV-1 RNA) and general indicators
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of organ system injury (hemoglobin, platelets, AST and ALT, FIB-4, creatinine, and
HCV infection) to indicate increasing risk of all-cause mortality with increasing score
(99). Not only does the VACS Index discriminate mortality risk more effectively than
traditional indices restricted to CD4 count, HIV-1 RNA, and age, but it also predicts
many other health outcomes in people living with HIV infection and has been validated
in several European and North American cohorts (101, 102). The VACS Index has been
shown to predict outcomes after admission for bacterial pneumonia, medical intensive
care unit admission and fragility fractures, weight gain in the first 12 months after ART
initiation, and acute myocardial infarction (103-109). We found that the VACS Index
score differed significantly between progressors and non-progressors; however, the
presence of Hepatitis C and the FIB-4 score which was the basis for our outcome
variable, are included in the VACS Index calculation. A multivariate model that included
all of the elements of the VACS Index except for Hepatitis C infection and FIB-4 score
did not achieve statistical significance.
There are several limitations to our study. The relatively small sample size might
not have afforded us enough power to achieve statistical significance for the observed
differences for variables that one would expect to show significance based on prior
studies, including low CD4 count, high HIV viral load, diabetes, hyperlipidemia, and
alcohol use disorder. An alternative explanation is that the HIV/HCV co-infected
population is already at higher risk of fibrosis progression and cannot be further
subdivided into increasing risk categories. Although FIB-4 has been well validated in
HIV/HCV co-infected populations as an accurate method of assessing liver fibrosis, FIB4 values may fluctuate due to other comorbid conditions, both intrahepatic (hepatic injury
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due to medications, alcohol, infections) and extrahepatic (sepsis, thrombocytopenia due
to immune dysregulation or immune suppression), which may not truly reflect fibrosis
severity. (33) In addition, our laboratory results were not restricted to those obtained in
the outpatient setting and included some tests such as transaminases obtained during
acute illness. However, we tried to mitigate the impact of FIB-4 fluctuations by taking the
mean of 3 FIB-4 scores to obtain the annual FIB-4 score. Although it is possible that
relying on a single non-invasive marker such as FIB-4 score to assess fibrosis severity
may have influenced our findings, we found that the FIB-4 score showed strong
concordance with liver biopsy stages in differentiating cirrhotic and non-cirrhotic patients
out of the 38 patients who had ever received a liver biopsy. There were only 3 patients in
our study with biopsy proven cirrhosis, and in 2 out of the 3 patients, the liver biopsies
were obtained during the 5 year study period and corresponded to annual FIB-4 scores of
4.10 and 7.31. The study was also limited by missing data. For example, the duration of
HCV infection was only documented in a minority of patients, but this information would
have been useful for determining whether those who progressed faster had been infected
with HCV for a longer duration.
Our study could also have been influenced by disease spectrum bias; those who
progressed had higher mean FIB-4 scores at 5 years prior to study entry compared to nonprogressors (2.49 vs 1.73; Figure 1), and may have represented individuals with a longer
duration of HCV infection. However, there was no statistically significant difference in
age between the 2 groups which would make this bias less likely. Although most patients
had been infected with HCV for well over a decade, the study duration was limited to 5
years and may not have fully captured the natural history of fibrosis progression in this
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population. Therefore, further observation over a longer duration of 10-15 years in a
larger pool of patients may have detected smaller and more long-term effects.
Data extracted from problem lists and chart review may not have completely
captured variables such as alcohol use disorder; therefore, we also extracted information
about AUDIT scores, which were routinely obtained at every outpatient visit. Yet it is
possible that we underestimated the degree of alcohol intake. Our study was limited to
patients receiving care at a single outpatient clinic and patients who were initially
cirrhotic (FIB-4>3.25) were excluded, further reducing the sample size (N=93).
In conclusion, in this cohort of HIV/HCV-infected patients receiving care at a
single clinic, based on FIB-4 score measurements, a quarter had significant fibrosis
progression over a 5-year interval. There were no significant predictors of progression,
although certain measures of HIV virologic control such as HIV viral load and CD4
count at study entry tended to correlate with fibrosis progression.
Our study cannot fully exclude the impact of these factors, and further research is
needed to identify the factors that influence fibrogenesis through large, prospective
natural history studies. It is notable that information from this study provides valuable
insight into which variables should be utilized for testable hypotheses in future studies.
What are the potential implications of our findings for prioritizing treatment with DAAs?
While others might consider a “wait and see” approach feasible given that many patients
in our study did not progress to cirrhosis based on FIB-4 scoring over 5 years, our
findings did not identify any reliable predictors of fibrosis progression. Thus, universal
treatment with DAAs would likely be the best approach and may be more readily
implementable as HCV medication prices decline in the future.
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